High Throughput AD Drug Screening of Alpha-Secretase Activity Modulators as a Novel Model for Alzheimer's Disease
ISEF · 2015 Translational Medical Science Third Award
Overview
Due to the increasing prevalence of Alzheimer’s Disease (AD) and currently the absence of effective disease modifying drugs, there is a need for improved drug screens to identify plausible AD disease drugs. Amyloid Precursor Protein (APP) can be converted to sAPP a, a harmless form of APP metabolism and is a competing pathway for the generation of beta-amyloid. a -Secretases can be activated by several pathways involving receptor mediated activation and direct PKC modulation of a –secretase activity. The present study investigates a way to inhibit the formation of ß –amyloid (Aß) plaques which results in the progressive form of dementia known as Alzheimer’s Disease. This study suggests the use of modified HEK293e cells and SH-SY5Y neuroblastoma cells as a novel method for the screening of a candidate drug, Bryostatin, under the Aß hypothesis. By treating models of brain cells (HEK293e) and SH-SY5Y neuroblstoma cells with drugs such as Bryostatin, which is derived from the sea moss Bugula Neritina, a-secretase can be upregulated through Protein Kinase Chain (PKC) modulation. Therefore, the non-toxic form of APP (sAPPa) can be produced and a method to treat AD may be achieved. Upon treatment, it was found that Bryostatin isoforms 1,2,3,10,12,14b, and 16 are potent activators of a-secretase expression in both concentrations tested. (10^-7 and 10^-8 M). These results suggest that Bryostatin could be a promising and novel drug to be used as a low-dose therapy for AD and may help move this drug towards clinical trials for the treatment for AD.
Awards (1)
- Third Award of $1,000 $1,000
Competition history
- ISEF 2015
Resources
Related projects
ISEF · 2026
A Multi-Target Chronopharmacotherapy for the Inhibition and Clearance of Toxic Proteins in Alzheimer's Disease
ISEF · 2026
Discovering a Path from Molecular Modeling to Alzheimer's Phytotherapeutics: Characterizing Novel GSK3ß Inhibitors in silico and in vitro
ISEF · 2014
Development of a Therapeutic Drug for Alzheimer’s Disease: A Chemical Approach to Cease Amyloidosis
ISEF · 2023
Identifying Novel Drugs to Inhibit APOE4 as a Therapeutic Intervention for Treating Alzheimer's
ISEF · 2014
A New Pathway for Alzheimer’s Drugs: Modification of BACE1 to Decrease the Release of Beta Amyloid in the Brain
ISEF · 2021
Identification of a Potential Beta-site Amyloid Precursor Protein Cleaving Enzyme-1 Inhibitor as a Disease Modifying Agent for Alzheimer's Disease
ISEF · 2022
In silico High-Throughput Identification of Novel Dual Amyloid Beta and Tau Aggregation Inhibitors for Alzheimer's Disease Treatments
ISEF · 2021
The Identification and Validation of Novel Targets and Pathways of Alzheimer's Disease Through Integrated System Approaches
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair